Icatibant Medical Valley (Icatibant)

Icatibant works as a competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary drivers of swelling during hereditary angioedema attacks.

The dose of icatibant is determined by the prescribing healthcare professional based on the patient’s clinical condition and regulatory guidelines. The prescriber will decide the exact amount and frequency required for each acute HAE episode.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other treatments such as C1‑esterase inhibitor concentrates replace the deficient protein, and newer monoclonal antibodies target different pathways. Icatibant offers rapid subcutaneous administration, making it convenient for self‑treatment during attacks.

Icatibant should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Icatibant is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or by the patient after appropriate instruction, using a pre‑filled syringe or autoinjector.

Serious risks include anaphylaxis, severe hypotension, and paradoxical angioedema of the face or throat. Patients should be monitored closely after injection, and any signs of severe allergic reaction or worsening swelling require immediate medical attention.

Icatibant should not be used by individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with uncontrolled cardiovascular disease, and the drug should be avoided in situations where alternative approved therapies are more appropriate.